Clinical practice guidelines, meta-analysis, and systematic reviews are the highest ranked forms of evidence.
Respuesta
True
False
Pregunta 2
Pregunta
Māori are 3.4 times, and Pacific peoples 3.9 times, more likely to be admitted to hospital with asthma than Europeans or other New Zealanders.
Respuesta
True
False
Pregunta 3
Pregunta
When diagnosing asthma there is no single “gold standard” test, and we must assess the pattern of [blank_start]signs and symptoms[blank_end](wheezing, breathlessness, chest tightness, and coughing, particularly at [blank_start]night[blank_end] or [blank_start]early[blank_end] in the morning). We can also measure [blank_start]expiratory airflow[blank_end] on more than one occasion, and assess [blank_start]response[blank_end] to inhaled bronchodilator +/- inhaled corticosteroid.
Respuesta
signs and symptoms
night
early
expiratory airflow
response
Pregunta 4
Pregunta
Ideal PEFR values depend on height and sex.
Respuesta
True
False
Pregunta 5
Pregunta
Which of these is NOT a principle of asthma treatment?
Respuesta
Avoid triggers
Making an asthma plan
Drugs to improve ventilation
Drugs to decrease inflammation
Avoid exercise
Pregunta 6
Pregunta
Goals of asthma treatment are about maintaining long-term control using the [blank_start]least[blank_end] amount of medications and [blank_start]minimising[blank_end] adverse effects.
We want to prevent chronic [blank_start]symptoms[blank_end], require infrequent use ([blank_start]2[blank_end] or fewer days/week) of SABA, maintain normal or near-normal [blank_start]pulmonary[blank_end] function and maintain [blank_start]activity[blank_end] levels. We should assure patients’ and families’ [blank_start]satisfaction[blank_end] with asthma care. We also want to prevent exacerbations, the need for [blank_start]hospitalisation[blank_end], and prevent progressive [blank_start]loss[blank_end] of lung function.
Respuesta
least
minimising
symptoms
2
pulmonary
activity
satisfaction
hospitalisation
loss
Pregunta 7
Pregunta
Which of these is not a drug delivery device?
Respuesta
Soft mist inhaler (SMI) - only with LAMA products in NZ
Nebuliser
Dry power inhaler (DPI)
Metered-dose inhaler (MDI) - spacer chamber
Dry mist inhaler (DMI)
Pregunta 8
Pregunta
Treatment steps:
1. At initial diagnosis, all patients should use a [blank_start]SABA[blank_end], as required..
2. Add an [blank_start]ICS[blank_end] if patients have symptoms for more than [blank_start]two[blank_end] weeks. Often a big decision! (The usual dose in adults is [blank_start]budesonide 400 mcg[blank_end]/day.)
3. If control is not adequate, [blank_start]ICS dose[blank_end] can be increased.
4. If control is not adequate, combine [blank_start]ICS with a LABA[blank_end]. ([blank_start]Formoterol+budesonide[blank_end] can be used as a preventer and replace SABA.)
Patients can step up or down in order to achieve and maintain control.
Check adherence and inhaler [blank_start]technique[blank_end] at each step of the way!